Asset
SEVASEMTEN
EDGEWISE THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05160415 | phase1 | completed | 2021-12-28 | 2024-03-01 | Edgewise Therapeutics, Inc. | A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy |
| NCT04585464 | phase1 | completed | 2020-10-12 | 2021-11-15 | Edgewise Therapeutics, Inc. | A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults |
| NCT05492734 | phase1 | completed | 2022-08-12 | 2022-08-19 | Edgewise Therapeutics, Inc. | A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling |
| NCT06916897 | phase1 | completed | 2025-01-08 | 2025-02-22 | Edgewise Therapeutics, Inc. | A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers |
| NCT05730842 | phase1 | completed | 2023-01-12 | 2023-04-06 | Edgewise Therapeutics, Inc. | Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.